Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC

NCT06023758 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Locally Advanced Resectable Gastric Cancer

Interventions

DRUG: KN026
DRUG: KN046
DRUG: XELOX

Sponsor

Peking University